ION224 (IONIS-DGAT2Rx)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 2bActive
Key Facts
Indication
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase
Phase 2b
Status
Active
Company
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a commercial-stage biotech leader with a mission to discover and deliver life-changing RNA-targeted medicines. The company has achieved multiple industry firsts, including the first approved antisense drug, and has successfully transitioned from a research-focused entity to a fully integrated organization with its own commercial capabilities. Its strategy centers on independently launching medicines in neurology and cardiology while selectively partnering in other areas, backed by a deep, late-stage pipeline and a sustainable technology platform.
View full company profileTherapeutic Areas
Other Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM831 (MK-3655) | NGM Biopharmaceuticals | Phase 2b |
| Pegozafermin (BIO89-100) | 89bio | Phase 3 |
| Icosabutate | NorthSea Therapeutics | Phase 3 |
| Oxy210 | MAX BioPharma | Preclinical |
| NA-941 | Biomed | Phase 2A |
| PRO-MSH-001 | ProdIgY Biotech | Discovery |
| Undisclosed MASH Program | Syndya Therapeutics | Discovery |
| Partnered Program | Cellarity | Pre-clinical |
| Lanifibranor | Hepalys | Phase 1 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| ALG-055009 | Aligos Therapeutics | Phase 2 |
| CM-101 | Chemomab Therapeutics | Phase 2a |